DK1962094T3 - Detektionsmiddel og terapeutisk middel til højmalign brystcancer - Google Patents

Detektionsmiddel og terapeutisk middel til højmalign brystcancer

Info

Publication number
DK1962094T3
DK1962094T3 DK06834751.7T DK06834751T DK1962094T3 DK 1962094 T3 DK1962094 T3 DK 1962094T3 DK 06834751 T DK06834751 T DK 06834751T DK 1962094 T3 DK1962094 T3 DK 1962094T3
Authority
DK
Denmark
Prior art keywords
detective
therapeutic agent
breast cancer
malignant breast
high malignant
Prior art date
Application number
DK06834751.7T
Other languages
English (en)
Inventor
Yasushi Nakamura
Hironao Yasuoka
Masahiko Tsujimoto
Rieko Goto
Zenzaburo Tozuka
Kunio Momiyama
Kennichi Kakudo
Tomonori Takami
Original Assignee
Jcl Bioassay Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jcl Bioassay Corp filed Critical Jcl Bioassay Corp
Application granted granted Critical
Publication of DK1962094T3 publication Critical patent/DK1962094T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
DK06834751.7T 2005-12-14 2006-12-08 Detektionsmiddel og terapeutisk middel til højmalign brystcancer DK1962094T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005361030 2005-12-14
PCT/JP2006/325008 WO2007069709A1 (ja) 2005-12-14 2006-12-08 高悪性度乳癌の検出剤および治療剤

Publications (1)

Publication Number Publication Date
DK1962094T3 true DK1962094T3 (da) 2011-01-10

Family

ID=38163011

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06834751.7T DK1962094T3 (da) 2005-12-14 2006-12-08 Detektionsmiddel og terapeutisk middel til højmalign brystcancer

Country Status (6)

Country Link
US (2) US8030014B2 (da)
EP (1) EP1962094B1 (da)
JP (1) JP4157157B2 (da)
DE (1) DE602006017107D1 (da)
DK (1) DK1962094T3 (da)
WO (1) WO2007069709A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2359852A4 (en) * 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
JP6324730B2 (ja) * 2014-01-15 2018-05-16 地方独立行政法人 大阪府立病院機構 リンパ節郭清により得られた組織片中のリンパ節判別方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524644A1 (de) 1985-07-10 1987-01-15 Heyl Chem Pharm Undulin und dessen peptidfragmente, verfahren zu deren herstellung und ihre verwendung
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
JP2004151003A (ja) 2002-10-31 2004-05-27 Hiroko Nogi Ｍｕｃ１およびケラチン１９の検査方法
WO2004097030A2 (en) 2003-04-28 2004-11-11 Bristol-Myers Squibb Company Prognostic breast cancer biomarkers

Also Published As

Publication number Publication date
US20110111414A1 (en) 2011-05-12
WO2007069709A1 (ja) 2007-06-21
EP1962094A1 (en) 2008-08-27
EP1962094A4 (en) 2009-06-24
US8030014B2 (en) 2011-10-04
JP4157157B2 (ja) 2008-09-24
EP1962094B1 (en) 2010-09-22
US20100215648A1 (en) 2010-08-26
DE602006017107D1 (de) 2010-11-04
JPWO2007069709A1 (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
EP1967209A4 (en) THERAPEUTIC AGENT AGAINST PROSTATE CANCER
DK1802625T3 (da) Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer
IL188746A0 (en) Treatment of cancer
ZA200610132B (en) Therapy of platinum-resistant cancer
EP1876186A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER
EP1937845A4 (en) MICRO-RNA-BASED METHOD AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF BREAST CANCER
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
EP1869224A4 (en) METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCERS
GB0519405D0 (en) Cancer therapy prognosis and target
IL188430A0 (en) Treatment of tumors
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
FR2872704B1 (fr) Pluritherapie contre le cancer
DE602006013094D1 (de) Krebsmittel
EP1937831A4 (en) USE OF N-MYRISTOYLTRANSFERASE ON NON-TUMOR TISSUE FOR CANCER DIAGNOSIS
EP1937816A4 (en) CANCER DIAGNOSTIC MARKERS AND USE
EP1863520A4 (en) USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER
HK1164767A1 (en) Compounds and methods for the treatment of cancer
HK1110224A1 (en) Therapeutic agent for cancer
IL189377A0 (en) Combinations comprising dmxaa for the treatment of cancer
IL189376A0 (en) Combinations comprising dmxaa for the treatment of cancer
ITMI20051107A1 (it) Metodo per il trattamento del cancro
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
DK1962094T3 (da) Detektionsmiddel og terapeutisk middel til højmalign brystcancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0520067D0 (en) Treatment of cancer